TY - JOUR
T1 - Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors
T2 - A Promising Option
AU - He, Jiasen
AU - Munir, Faryal
AU - Ragoonanan, Dristhi
AU - Zaky, Wafik
AU - Khazal, Sajad J.
AU - Tewari, Priti
AU - Fueyo, Juan
AU - Gomez-Manzano, Candelaria
AU - Jiang, Hong
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/3
Y1 - 2023/3
N2 - Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved in decades, and alternative treatment options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells and oncolytic viruses (OVs), are currently being evaluated in both adults and children with refractory solid tumors. Because pediatric solid tumors are remarkably diverse and biologically different from their adult counterparts, more research is required to develop effective treatment regimens for these patients. Here, we first summarize recent efforts and advances in treatments for pediatric solid tumors. Next, we briefly introduce the principles for CAR T cell therapy and oncolytic virotherapy and clinical trials thereof in pediatric patients. Finally, we discuss the basis for the potential benefits of combining the two approaches in pediatric patients with advanced solid tumors.
AB - Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved in decades, and alternative treatment options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells and oncolytic viruses (OVs), are currently being evaluated in both adults and children with refractory solid tumors. Because pediatric solid tumors are remarkably diverse and biologically different from their adult counterparts, more research is required to develop effective treatment regimens for these patients. Here, we first summarize recent efforts and advances in treatments for pediatric solid tumors. Next, we briefly introduce the principles for CAR T cell therapy and oncolytic virotherapy and clinical trials thereof in pediatric patients. Finally, we discuss the basis for the potential benefits of combining the two approaches in pediatric patients with advanced solid tumors.
KW - cancer immunotherapy
KW - CAR T cell therapy
KW - oncolytic virotherapy
KW - oncolytic virus
KW - pediatric brain tumor
KW - pediatric solid tumor
UR - http://www.scopus.com/inward/record.url?scp=85162857131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162857131&partnerID=8YFLogxK
U2 - 10.3390/immuno3010004
DO - 10.3390/immuno3010004
M3 - Review article
AN - SCOPUS:85162857131
SN - 2673-5601
VL - 3
SP - 37
EP - 56
JO - Immuno
JF - Immuno
IS - 1
ER -